摘要
目的探讨艾司唑仑联合补肾益脑丸对失眠症的临床治疗效果。方法选择北京军区总医院第三门诊部就诊的失眠症患者65例（所有患者均符合中国精神疾病分类方案与诊断标准中失眠症的诊断标准，排除有躯体疾病或精神障碍症状导致的继发性失眠及外源性睡眠障碍者）。完全随机分为观察组（33例）和对照组（32例）。观察组应用艾司唑仑联合补肾益脑丸治疗；对照组服用艾司唑仑单药治疗。分别于治疗前及治疗3个疗程后，采用匹兹堡睡眠质量指数（PSQI）对观察组和对照组的睡眠质量进行评定。结果65例患者中完成研究62例；发生脱失3例，其中观察组脱失1例、对照组脱失2例，治疗3个疗程后，观察组与对照组比较，PSQI评分总分下降幅度大于对照组，差异有统计学意义（P〈o．05）。2组治疗后患者的入睡时间缩短，PSQI评分下降[对照组分别为（2．1±0．5）分比（0．6±0．4）分，观察组分别为（2．1±0．5）分比（0．63±0．41）分]，睡眠时间均延长，PSQI评分下降[对照组分别为（1．9±0．3）分比（1．0±0．6）分，观察组分别为（1．9±0．5）分比（0．9±0．6）分]，睡眠质量、睡眠效率提高，差异有统计学意义（均P〈0．01）。与对照组治疗后比较，观察组患者日间功能障碍减少，差异有统计学意义（P〈0．05）。结论艾司唑仑联合补肾益脑丸治疗失眠症有较好的治疗效果，并能减少艾司唑仑的不良反应。
Objective To study the clinical effect of insomnia patients treated by estazolam combined with bushenyinaowan. Methods All 65 patients with insomnia were chosen according to the diagnostic criteria of mental disorders; patients with secondary and/or exogenous insomnia were excluded. The 65 cases were randomly divided into 2 groups. 33 patients in the observing group received estazolam combined with bushenyinaowan; 32 patients in the control group only received estazolam. After 3 courses of treatment, the sleep quality of the 2 groups were as- sessed according to pittsburge sleep quality index（PSQI）. The result arranged from 0 to 21 and the high PSQI point accounted for bad sleep quality. Results After 3 courses of treatment, 1 case in the observing group and 2 cases in the control group dropped out; the decrease of PSQI point was significantly higher in observing group than that in control group, P 〈 0.05. Compared with control group, patients in observing group had less day time function disor- ders, P 〈 0.05. Conclusion In insomnia patients, bushenyinaowan and estazolam can bring significant improve- ment of clinical efficacy and reduce the adverse reaction of estazolam.
出处
《中国医药》
2012年第7期848-849,共2页
China Medicine
